Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Remifentanil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 14/20 | 0.77 |
| ▸ | CACNA1C | Q13936 | 1/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.77 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Remifentanil SCHEMBL17874058 | 1.00 | CACNA1C (1.00) | CACNA1COPRM1OPRD1OPRK1 | |
| Remifentanil SCHEMBL3711219 | 0.99 | CACNA1C (0.98) | CACNA1COPRM1OPRD1OPRK1 | |
| Remifentanil SCHEMBL29846323 | 0.99 | CACNA1C (0.98) | CACNA1COPRM1OPRD1OPRK1 | |
| Remifentanil SCHEMBL41242 | 0.99 | CACNA1C (0.98) | CACNA1COPRM1OPRD1OPRK1 | |
| Remifentanil SCHEMBL3423820 | 0.99 | CACNA1C (0.98) | CACNA1COPRM1OPRD1OPRK1 | |
| Remifentanil SCHEMBL27828413 | 0.98 | CACNA1C (0.96) | CACNA1COPRM1OPRD1OPRK1 | |
| Remifentanil SCHEMBL1649640 | 0.98 | CACNA1C (0.96) | CACNA1COPRM1OPRD1OPRK1 | |
| Remifentanil SCHEMBL8446617 | 0.95 | CACNA1C (0.90) | CACNA1COPRM1OPRD1OPRK1 | |
| Carfentanil SCHEMBL16444962 | 0.94 | OPRM1 (0.89) | CACNA1COPRM1OPRD1OPRK1 | |
| Remifentanil SCHEMBL4384648 | 0.94 | CACNA1C (0.89) | CACNA1COPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 12890 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122087518-A | Method for classifying anesthetic drugs by using neural network | — | 2026-05-26 | — | — | CN | claimed |
| US-12635940-B2 | Closed-loop drug infusion system with synergic control | UNIVERSIDAD POLITÉCNICA DE MADRID FUNDACION PARA LA INVESTIGACIÓN E INNOVACIÓN BIOMÉDICA (ES) | 2026-05-26 | — | — | US | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| EP-4719552-A1 | INDUCTION OF GENERAL ANESTHESIA IN ADULTS UNDERGOING ELECTIVE SURGERY | Xizang Haisco Pharmaceutical Co., Ltd. (CN) | 2026-04-08 | — | — | EP | claimed |
| US-20260069777-A1 | Systems and methods for controlled delivery of analgesic and hypnotic agents | NEUROWAVE SYSTEMS INC. (CA) | 2026-03-12 | — | — | US | claimed |
| CN-121577732-A | Method for rapidly detecting remifentanil blood concentration | 中国科学院大连化学物理研究所 | 2026-02-27 | — | — | CN | claimed |
| US-20260027128-A1 | ORALLY INHALED AND NASAL BENZODIAZEPINES | PAION UK LTD (GB) | 2026-01-29 | — | — | US | claimed |
| US-20260027337-A1 | TRANSDERMAL DRUG DELIVERY DEVICES AND METHODS | MORNINGSIDE VENTURE INVESTMENTS LTD (MC) | 2026-01-29 | — | — | US | claimed |
| US-20260021038-A1 | Compositions and Methods for the Treatment of Opioid Overdose | INDIVIOR INC (US) | 2026-01-22 | — | — | US | claimed |
| EP-4680244-A1 | SEROTONIN 5HT2A RECEPTOR ANTAGONIST FOR USE IN TREATING SIDE EFFECTS RESULTING FORM MU OPIOID RECEPTOR AGONIST OVERDOSE | Norwegian University Of Life Sciences (NO) | 2026-01-21 | — | — | EP | claimed |
| WO-1998035888-A1 | METERING VALVE FOR AEROSOLS | GLAXO GROUP LIMITED (GB) | 1998-08-20 | — | — | WO | claimed |
| EP-0759744-A4 | NARCOTIC CONTAINING AEROSOL FORMULATION | ARADIGM CORP (US) | 1997-10-29 | — | — | EP | claimed |
| US-5635204-A | Method for transdermal induction of anesthesia, analgesia or sedation | MONTEFIORE MEDICAL CENTER (US) | 1997-06-03 | — | — | US | claimed |
| EP-0759744-A1 | NARCOTIC CONTAINING AEROSOL FORMULATION | ARADIGM CORPORATION (US) | 1997-03-05 | — | — | EP | claimed |
| EP-0726864-A1 | METERED AEROSOL DISPENSING APPARATUS AND METHOD OF USE THEREOF | GLAXO WELLCOME INC. (US) | 1996-08-21 | — | — | EP | claimed |
| EP-0383579-B1 | N-Phenyl-N-(4-piperidinyl)amides useful as analgesics | GLAXO WELLCOME INC (US) | 1996-07-17 | — | — | EP | claimed |
| WO-1995031182-A1 | NARCOTIC CONTAINING AEROSOL FORMULATION | ARADIGM CORPORATION (US) | 1995-11-23 | — | — | WO | claimed |
| US-5421492-A | Metered aerosol dispensing apparatus and method of use thereof | GLAXO INC. (US) | 1995-06-06 | — | — | US | claimed |
| WO-1995012533-A1 | METERED AEROSOL DISPENSING APPARATUS AND METHOD OF USE THEREOF | GLAXO WELLCOME INC. (US) | 1995-05-11 | — | — | WO | claimed |
| EP-0383579-A1 | N-Phenyl-N-(4-piperidinyl)amides useful as analgesics | GLAXO WELLCOME INC. (US) | 1990-08-22 | — | — | EP | claimed |